Migraine

 
Atogepant: Pivotal Phase 3 Study Meets Primary Endpoint for Preventive Treatment of Chronic Migraine
March 10, 2022

Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.

Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
March 10, 2022

Consider migraine screening for all women aged 20 to 50 years, suggests Ailani; you'll likely find a majority of them have migraine. More pearls follow.

Migraine-specific Preventive Therapies Can Be a Primary Care Tool, Leading Investigator Says
March 09, 2022

Migraine-specific preventive therapies should be in the primary care toolbox, according to headache specialist Jessica Ailani, MD.

Migraine Perspectives with Jessica Ailani, MD: Start Migraine Care in Primary Care
March 09, 2022

Migraine headache specialist and researcher Jessica Ailani, MD, fully supports primary care as the setting for the majority of the treatment for the disease.

10 Questions on Migraine Impact, Diagnosis, & Treatment Based on the OVERCOME Study
March 08, 2022

Lifetime use of opioids for migraine was found to be higher than for triptan medications. Try these 10 questions on other OVERCOME findings.

Unmet Needs in US Migraine Headache Management: OVERCOME Study First Data
March 03, 2022

Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.

Largest Genetic Study of Migraine to Date Identifies New Risk Factors
March 02, 2022

Researchers identified over 120 regions connected to risk of migraine, of which 86 were previously unknown.

Migraine Linked to Higher Risk of Pregnancy Complications in Preliminary Study
February 28, 2022

Researchers also found that women with migraine with aura had a higher risk of preeclampsia than those with migraine without aura.

Intranasal Zavegepant for Migraine Meets Coprimary Regulatory Endpoints in Pivotal Phase 3 Trial
December 09, 2021

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.

8 New Drugs Approved for Primary Care: Q3 2021
October 08, 2021

The first vaccine against COVID-19, 2 new treatments for migraine, a novel topical agent for atopic dermatitis, and 4 more recently approved drugs of interest to primary care.